J 2019

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

KREJČÍ, Pavel

Basic information

Original name

C-Type Natriuretic Peptide Analogue Therapy in Children with Achondroplasia

Authors

KREJČÍ, Pavel (203 Czech Republic, guarantor, belonging to the institution)

Edition

New England Journal of Medicine, Waltham, Massachussetts Medical Society, 2019, 0028-4793

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10608 Biochemistry and molecular biology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 74.699

RIV identification code

RIV/00216224:14110/19:00112475

Organization unit

Faculty of Medicine

DOI

UT WoS

000489333500020

Keywords in English

Achondroplasia; C-type natriuretic peptide

Tags

Tags

International impact
Změněno: 4/3/2020 14:30, Mgr. Tereza Miškechová

Abstract

V originále

Savarirayan et al. (July 4 issue)1 report increased skeletal growth in patients with achondroplasia (a common type of dwarfism caused by activating mutations in the tyrosine kinase fibroblast growth factor receptor 3 gene FGFR3) who received vosoritide, a stable analogue of C-type natriuretic peptide. Their study is a breakthrough in treatment for achondroplasia, and it offers an intriguing possibility of broader clinical applications.

Links

MUNI/A/1087/2018, interní kód MU
Name: Molekulární a buněčná biologie pro biomedicínské vědy
Investor: Masaryk University, Category A